The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide ...
A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...